Woojin B&G Secures Korea's First Patent for Goat "Caseous Lymphadenitis" Preventive Vaccine

Woojin B&G has become the first company in Korea to secure a patent for a vaccine to prevent Caseous Lymphadenitis (CLA) in goats, embarking on a strategy to target the rapidly growing domestic goat industry.

On May 21, Woojin B&G announced that it had obtained a patent for a novel strain isolated from goats infected with Caseous Lymphadenitis and for a prophylactic vaccine composition utilizing this strain.

The subject of this patent is "IMMUNIS CoryVac," an inactivated vaccine currently under development based on pathogens isolated from Korean goat farms.

Caseous Lymphadenitis, also known as "pseudotuberculosis," is a chronic bacterial infectious disease that forms abscesses in the lymph nodes and internal organs of goats. Although the mortality rate is not high, infection leads to growth retardation and decreased marketability, causing significant losses for farmers. In particular, since the disease can spread for long periods through contaminated environments, preventative vaccine management is considered more important than treatment.

The domestic goat industry has been growing rapidly in recent years, yet there remains a shortage of dedicated vaccines and veterinary pharmaceuticals. Against this backdrop, the government has highlighted the necessity for developing vaccines to combat major diseases like Caseous Lymphadenitis through its “Goat Industry Development Plan.” Industry observers are therefore viewing this patent as a meaningful achievement for strengthening Korea’s disease management system for goats.

The efficacy of the vaccine has also been confirmed. Woojin B&G explained that clinical trials conducted on black goats at a farm in Gokseong, Jeollanam-do, showed no adverse effects such as high fever or mortality in the vaccinated group. In contrast, the vaccine demonstrated excellent antibody formation capability and suppression of abscesses.

In particular, the company stated that even in challenge tests where the bacteria were forcibly injected after vaccination, no bacteria were detected, confirming a high level of protective efficacy.

Woojin B&G plans to pursue product item approval next year based on this patent. The company also intends to expand its vaccine lineup to cover other major diseases affecting goat farms, such as botulism, stomatitis, and mastitis.

A company representative said, "It is significant that we are able to contribute to the national task of developing multi-disease vaccines in line with the government’s ‘2026 Goat Industry Development Plan.’ Through the launch of IMMUNIS CoryVac, we aim to help improve farm profitability and enhance the hygiene and safety of domestically produced goat meat."

This patent acquisition is expected to help Woojin B&G secure a leading position in the domestic goat disease prevention market and further strengthen its competitiveness in the animal vaccine business.

This content was produced with the assistance of AI translation services.